| 131I难治性分化型甲状腺癌的再分化治疗 |
| |
| 引用本文： | 程凌霄,陈立波.131I难治性分化型甲状腺癌的再分化治疗[J].中国癌症杂志,2016,26(1):35-42. |
| |
| 作者姓名： | 程凌霄 陈立波 |
| |
| 作者单位： | 上海交通大学附属第六人民医院核医学科，上海 200233 |
| |
| 基金项目： | 国家自然科学基金，上海市科技启明星 |
| |
| 摘 要： | 131I难治性分化型甲状腺癌(radioiodine-refractory differentiated thyroid cancer，RR-DTC)是目前甲状腺癌临床治疗领域的一大难题。维甲酸类药物、过氧化物酶体增殖物激活受体激动剂、DNA甲基化酶抑制剂及组蛋白脱乙酰化酶抑制剂都曾被用于诱导RR-DTC再分化并与131I联合治疗，但疗效并不显著。近年来，随着对RR-DTC分子机制认识的不断深入，靶向治疗等新的再分化治疗策略越来越多地被尝试用于治疗RRDTC。相比之下，分子靶向药物用于诱导RR-DTC重摄碘及介导131I治疗效果较好，可能具有良好的应用前景。
|
| 关 键 词： | 甲状腺癌 再分化治疗 靶向药物 131I |
Re-differentiating therapy of radioiodine-refractory differentiated thyroid cancer |
| |
| CHENG Lingxiao,CHEN Libo.Re-differentiating therapy of radioiodine-refractory differentiated thyroid cancer[J].China Oncology,2016,26(1):35-42. |
| |
| Authors: | CHENG Lingxiao CHEN Libo |
| |
| Institution: | Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai 200233, China |
| |
| Abstract: | Clinical management of radioiodine-refractory differentiated thyroid cancer (RR-DTC) is extremely diffcult. Re-differentiation compounds, such as retinoids, peroxisome proliferator-activated receptor (PPAR) agonists, DNA methyltransferase inhibitors and histone deacetylase inhibitors, have been used in trials to increase iodine uptake in RR-DTC. However, data on these drugs failed to meet the initial high expectations. In recent years, targeted agents have been increasingly used in pre-clinical and clinical studies to induce re-differentiation and mediate131I therapy, and the outcomes are encouraging. |
| |
| Keywords: | Thyroid cancer Re-differentiating therapy Targeted agents 131I |
| 本文献已被 万方数据 等数据库收录！ |
| 点击此处可从《中国癌症杂志》浏览原始摘要信息 |
| 点击此处可从《中国癌症杂志》下载免费的PDF全文 |
